NON-HODGKIN'S LYMPHOMA

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The goal is to track long-term safety and side effects. About 165 adults are taking part, and they must continue to tolerate the drug well.

This early-phase study tests a new approach for people with CD19-positive blood cancers (like lymphoma or leukemia) that returned after a stem cell transplant. Researchers take immune cells (T cells) from the original stem cell donor, modify them to better recognize and attack ca…

This early-stage study tests a new treatment called SC262 for people with Non-Hodgkin's lymphoma that has come back or not responded to other therapies. SC262 uses donor immune cells that are modified to target and attack cancer cells. The main goal is to check safety and see if …

This study looks at whether giving palifermin and leuprolide acetate can speed up immune recovery in people who have had a stem cell transplant for blood cancers like leukemia or lymphoma. The transplant uses donor stem cells to replace the patient's blood system. The goal is to …

This early-stage study tests a new drug called ABBV-525 in people with B-cell cancers like lymphoma and leukemia. The goal is to find a safe dose and see if it can shrink tumors. About 78 adults will take the drug by mouth at different doses over several months.

This study tests a new drug called glofitamab, which helps the immune system attack cancer cells. It is for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to other treatments. The study aims to find the best dose and check if the drug is safe and ef…

This study tests whether combining two drugs—obinutuzumab and ibrutinib—can shrink or eliminate slow-growing non-Hodgkin's lymphoma in people who haven't been treated before. About 30 adults with various stages of the disease will receive the drugs as their first therapy. The goa…

This early-phase study tested whether giving patients their own genetically modified immune cells (CAR T-cells) after high-dose chemotherapy and a stem cell transplant is safe for treating aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Sev…

This study tests whether combining copanlisib and rituximab can slow or stop the growth of follicular lymphoma, a type of blood cancer. About 33 adults who have not yet been treated for their disease will receive the drugs through an IV over up to 13 cycles. The main goal is to s…

This early-phase study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has come back or not responded to standard therapy. Researchers take a patient's own immune cells (T cells), add a special receptor that targets the CD30 protein found on lymphoma ce…

This early-phase study uses a tiny amount of a radioactive drug called 124I-PUH71 to take PET scans of cancer patients. The goal is to see where the drug goes in the body, including into tumors, and how long it stays in the blood. About 63 people with lymphoma, myeloma, or other …

This study collects white blood cells from people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are used to create a personalized therapy called CAR T-cells, which may be given later. The procedure, called leukapheresis, takes 4-6…